SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

Apr 19, 2024 - 00:00

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

Read the original article

Tags:

Previous Article

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease

UAE approves BioArctic and Eisai’s Leqembi for Alzheime...

Aug 15, 2024

Dexmedetomidine by Teikoku Pharma USA for Post-Operativ...

Jul 7, 2023

Genprex’s Reqorsa gene therapy picks up orphan drug designation from FDA for SCLC

Genprex’s Reqorsa gene therapy picks up orphan drug des...

Aug 12, 2023